



MedStar Health

MedStar Health Ambulatory Best Practice Group Recommended Screening Guidelines 2014

The Ambulatory Best Practice Group, chartered in 2001 by Dr. William Thomas is composed of experts in primary and family health care from across our system. This group of physicians and nurses meets on a regular basis to evaluate the quality of care delivered across the system while staying abreast of trends in healthcare that will impact ambulatory practice and care outcomes.

During the preparation of these screening guidelines, the Ambulatory Quality Best Practices Group reviews multiple sources of information including current literature, community practice standards, subject matter experts from within our system, national recommendations from clinical specialty organizations and information available regarding recommendations for health and prevention screening guidelines.

This document is a summary of our recommendations for the appropriate screening of patients in MedStar Health. These recommendations are for adult, pediatric and special populations across our system. The document is divided into a section for Adults and Pediatrics. In each of the sections the recommendations are alphabetized. This reference is intended for all providers who serve as primary care practitioners for ambulatory patients in the MedStar Health system.

Successful implementation of the screening guidelines is at least in part related to a successful education process for providers, patients and families. To that end, we have included information that is available free of charge through specific Internet sites. At times the information on the Internet sites discusses some recommendations that have not been put forward in this document so elimination of that information is an important consideration prior to printing and distribution of the information.

These recommendations are provided to assist physicians and other clinicians making decisions regarding the care of their patients. As such, they cannot substitute for the individual judgment brought to each clinical situation by the patient's primary care provider. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but should be used with the clear understanding that continued research may result in new knowledge and recommendations.

Federal and state law, particularly laws and regulations relative to provision of care under governmental programs such as Medicare/Medicaid, may mandate the provision of certain screening and preventive care. Any questions regarding these requirements should be reviewed with legal counsel or a member of our committee. Member names and phone numbers are listed on the next page of this document.

The Ambulatory Best Practice Group will review these guidelines on an annual basis for additions, deletions or clarifications and distribute as appropriate.

Ambulatory Best Practice Group Members

Chair

Edward Miller, MD MedStar Medical Group 443-725-8719

Co- Chair

Carmella Cole, MD Washington Hospital Center 202-877-8485

Members

Nancy Barr MD MedStar Health – FSH 443-777-7676
Peter Basch, MD MedStar Medical Group 202-546-4504
Eula Beasley PharmD MedStar Health Pharmacy 410-540-4424
Stephanie R Bruce MD MedStar Health – WHC 202-877-0218
Alyssa Cook MD MedStar Health – FSH 443-777-7155
Jean DeCosmo, BSN MedStar Corporate Quality – Director 410-772-6576
Deva, Shikha MD MedStar Medical Group 301-926-3095
Mike Donnelly MD MedStar Health GUH 202-444-8866
Michael Dwyer MD MedStar Health - FSH 443-777-2040
Joyce Falkenhan MSN MedStar Medical Group 443-725-8823
Chris Goeschel, ScD, MPA Medstar Corporate Quality - AVP 410-772-6683
Laura Hofmann MD MedStar Medical Group 202-797-4950
Meng Jin MedStar Medical Group 443-725-8702
Robert Krainak, RN MedStar Health GUH 202-444-0431
Bonnie Levin PharmD MedStar Health Pharmacy - AVP 301-680-7881
Rosemarie Maraj MD MedStar Health – GSH 443-444-4818
Eileen Moore MD MedStar Health GUH 202-444-6686
Jessica Neil MedStar Health – FSH informatics 443-777-8428
Cathy Okuliar MD MedStar Health GUH 202-444-3009
Tara Saggar MD MedStar Southern Maryland 301-843-0222
Julie Seely MD Evolent Health 571-389-6000
Karen Streat CRNP MedStar Medical Group 443-725-8251
George Taler. MD MedStar Health VNA 202-877-0218
Patryce Toye, MD MedStar Family Choice 410-933-2218
Richard Walsh MD MedStar Medical Group 410-247-0782
Jeff Weinfeld MD MedStar Georgetown University 202-237-0015
Uchechi Wosu, MD MedStar Medical Group 301-899-0020
Radhika Vij MD MedStar Health - UMH 410-554-6420
Carlos Zigel MD MedStar Medical Group 410-350-3565
Catherine Zimmerer MSN MedStar Medical Group 443-725-8252

Ambulatory Best Practice Sub- Committee: Pediatric Best Practice Group Members

Chair

Lee A Fireman, MD	MedStar Health- FSH	443-777-7128
-------------------	---------------------	--------------

Members

Jean DeCosmo, BSN	MedStar Corporate Quality – Director	410-772-6576
Michael Dwyer, MD	MedStar Health – FSH	443-777-2040
Joyce Falkenhan MSN	MedStar Medical Group	443-725-8823
Chris Goeschel, ScD, MPA	Medstar Corporate Quality - AVP	410-772-6683
Kirsten.Hawkins, MD	MedStar Health – GUH	202-444-8668
Meng Jin MHA	MedStar Medical Group	443-725-8702
Gaurav Kumar, MD	MedStar Health – FSH	443-777-7129
Matt Levy MD	MedStar Health- Division Chief	202-444-8135
Edward Miller, MD	MedStar Medical Group	443-725-8719
Jessica Neil	MedStar Health – FSH informatics	443-777-8428
Ann Richmond, MD	MedStar Health – GUH	202-444-8581
Dena Schnitzer	MedStar Health – FSH	
Karen Streat CRNP	MedStar Medical Group	443-725-8251
Patryce Toye, MD	MedStar Family Choice	410-933-2218
Elaine Wilson MD	MedStar Medical Group	410-554-5437
Catherine Zimmerer MSN	MedStar Medical Group	443-725-8252

Adult Populations

Preventive Service	Guideline
Abdominal Aortic Aneurysm ¹⁷	One-time screening for abdominal aortic aneurysm by ultrasonography in men age 65 to 75 years who have ever smoked.
Aspirin chemoprevention ^{22, 25, 37}	Discuss aspirin chemoprevention with adults who are at increased risk for Cardiovascular Disease. Encourage aspirin therapy for men 45 to 79 years when the potential benefit of a reduction in myocardial infarctions outweighs the potential harm of an increase in gastrointestinal hemorrhage and women age 55 to 79 years when the potential benefit of a reduction in ischemic strokes outweighs the potential harm of an increase in gastrointestinal hemorrhage.
Blood Pressure ⁹	18 years and then at each visit. At least every 1-2 years.
Breast Cancer Screen ◦ Self Breast Exam (SBE) ^{9, 26}	Beginning in their 20's, women should be told about the benefits and limitations of BSE, it is acceptable for women to choose not to do BSE, or to do it occasionally. The importance of promptly reporting changes to a physician is emphasized.
◦ Clinical Breast Exam/Mammography ^{32,36}	A clinical breast exam (CBE) may be performed every 3 years for women between ages 20-39 <i>with average breast cancer risk</i> . Yearly CBE and Mammography for \geq age 40. Women known to be at increased risk (Family history, Positive Gail risk screen ³⁶) may benefit from earlier initiation of early detection testing and/or referral to Breast Specialist. Screening Mammograms for women > 75 years of age should be discussed between patient and provider. (MedStar Breast Expert Workgroup, panel discussion recommendations, January 8, 2010)
Cervical Cancer Screening ^{35,15}	<p>Cervical cancer screening should begin at age 21 years (regardless of sexual history). <i>Screening before age 21 should be avoided because women less than 21 years old are at very low risk of cancer. Screening these women may lead to unnecessary and harmful evaluation and treatment</i> (ACOG 2009).</p> <ul style="list-style-type: none"> • Women from ages 21 to 30 should be screened every three years, using either the standard Pap or liquid-based cytology. • Women age 30 and older who have had three consecutive negative cervical cytology test results may be screened once every three years with either the Pap or liquid-based cytology. • Women with certain risk factors may need more frequent screening, including those who have HIV, are immunosuppressed, were exposed to diethylstilbestrol (DES) in utero, and have been treated for cervical intraepithelial neoplasia (CIN) 2, CIN 3, or cervical cancer.(ACOG- 2009) • (HPV co-test (cytology + HPV test administered together) should not be used for women aged <30 years; Age 30-65 years, HPV co-test is strongly recommended every five years) • May discontinue screening > 65years for women with 3 consecutive normal Paps (USPSTF, 2003). • May discontinue screening >65 years(with adequate screening history)
Chlamydia Infection ¹⁷	Sexually active women aged 25 years and younger and other asymptomatic women at increased risk for infection.
Cholesterol Screening ²³	Screening of all adults should begin with fasting Lipoprotein panel every 5 years at age 20. Individuals with known risk factors of CHD or CHD should be tested earlier.
Colorectal Cancer Screening ³⁴	<p>Beginning at age 50, both men and women at <i>average risk</i> for developing colorectal cancer should use one of the screening tests below. The tests that are designed to find both early cancer and polyps are preferred if these tests are available to you and you are willing to have one of these more invasive tests. Talk to your doctor about which test is best for you. (ACS 2009)</p> <p>Tests that find polyps and cancer</p> <ul style="list-style-type: none"> ▪ flexible sigmoidoscopy every 5 years* ▪ colonoscopy every 10 years ▪ double contrast barium enema every 5 years* ▪ CT colonography (virtual colonoscopy) every 5 years* (consider community availability)

Preventive Service	Guideline			
	<p>Tests that mainly find cancer</p> <ul style="list-style-type: none"> ▪ fecal occult blood test (FOBT) every year*, ** ▪ fecal immunochemical test (FIT) every year*, ** ▪ stool DNA test (sDNA), interval uncertain* consider community availability) <p>*Colonoscopy should be done if test results are positive. **For FOBT or FIT used as a screening test, the take-home multiple sample method should be used. A FOBT or FIT done during a digital rectal exam in the doctor's office is not adequate for screening.</p> <p>Screening should be considered earlier and/or more often for individuals with any of the following colorectal cancer risk factors: personal Hx of colorectal cancer, a personal history of chronic inflammatory bowel disease (Crohns disease or ulcerative colitis), a strong family history of colorectal cancer or polyps (cancer or polyps in a first-degree relative [parent, sibling, or child] younger than 60 or in 2 or more first-degree relatives of any age), a known family history of hereditary colorectal cancer syndromes such as familial adenomatous polyposis (FAP) or hereditary non-polyposis colon cancer (HNPCC).</p>			
Counseling ¹⁵	<p>All adults, complete history using screening tools as specified. Alcohol & drug - use CAGE/Michigan assessment tool or similar tool.</p> <table border="0" style="width: 100%;"> <tr> <td style="vertical-align: top;"> <ul style="list-style-type: none"> ▪ Birth control/sexual behavior ▪ Violence detection/counseling ▪ Dental health ▪ Smoking </td> <td style="vertical-align: top; padding-left: 20px;"> <ul style="list-style-type: none"> ▪ Diet/nutrition ▪ Exercise ▪ Testicular self exam </td> <td style="vertical-align: top; padding-left: 20px;"> <ul style="list-style-type: none"> ▪ Injury Prevention ▪ Mental Health/Depression ▪ Skin Protection </td> </tr> </table>	<ul style="list-style-type: none"> ▪ Birth control/sexual behavior ▪ Violence detection/counseling ▪ Dental health ▪ Smoking 	<ul style="list-style-type: none"> ▪ Diet/nutrition ▪ Exercise ▪ Testicular self exam 	<ul style="list-style-type: none"> ▪ Injury Prevention ▪ Mental Health/Depression ▪ Skin Protection
<ul style="list-style-type: none"> ▪ Birth control/sexual behavior ▪ Violence detection/counseling ▪ Dental health ▪ Smoking 	<ul style="list-style-type: none"> ▪ Diet/nutrition ▪ Exercise ▪ Testicular self exam 	<ul style="list-style-type: none"> ▪ Injury Prevention ▪ Mental Health/Depression ▪ Skin Protection 		
Diabetes Mellitus ^{12, 25, 38}	<p>Screening by: fasting glucose test, impaired glucose test or A1C, individuals 45 years and older - screen, repeat every 3 years if normal. Consider testing in younger patients or perform more frequent testing in persons at increased risk for diabetes who meet the following criteria:</p> <ul style="list-style-type: none"> • Obesity (body mass index $\geq 30\text{kg/m}^2$- (if normal repeat q3 years). • 1st degree relative with diabetes. • Habitually physically inactive. • High-risk ethnic group (African American, Latino, Native or Asian Americans, Pacific Islanders). • Delivery of a baby weighing > 9 lbs. or gestational DM. • Hypertension ($\geq 140/90$). • Have PCOS, (polycystic ovary syndrome). • Plasma high-density lipoprotein cholesterol level ≤ 35 mg/dl or triglyceride level ≥ 250 mg/dl. • History of impaired glucose tolerance (140-199) or impaired fasting glucose level (100-125 mg/dl), or an A1C range of 5.7–6.4%. • History of vascular disease. 			
Depression ³³	<p>Screening for symptoms of depression should be at the initial visit for all new patients and then annually for existing patients. The patient may complete screening during the office visit with a patient self-reported questionnaire or using one of the various screening measures that have been specifically designed to detect depression. Physicians can choose the screening measures that are appropriate for their patients and practice setting, and for monitoring change in patients who are receiving treatment for depression.</p>			
Eye Disease Screening ²⁸	<p>Baseline screening should start at age 40 for adults with no signs or risk factors for eye disease. Patients of any age with eye disease risk factors, such as high blood pressure, family history or diabetes, should consult with their ophthalmologist about frequency of eye exams.</p>			
Hearing ^{14, 27}	<p>Providers should perform subjective hearing screening periodically with counseling on hearing aid devices and making referrals as appropriate.</p>			

Preventive Service	Guideline
Height and Weight ¹⁴ , BMI	18 years and older - Baseline height, weight and BMI indicated. Height and BMI annually. Weight Reduction Counseling for all patients with BMI > 25kg/m ²
Hepatitis C Screening	USPSTF & CDC recommend hepatitis C screening for all asymptomatic adults without known liver disease or functional abnormalities born between 1945-1965 (using code V73.89).
History & Physical	18 years and older - complete H&P at discretion of practitioner and patient. All Medicaid patients are required to have an annual health appraisal.
HIV Testing ²⁴	Testing for HIV infection should be performed routinely for all patients aged 13--64 years. All persons likely to be at high risk should be screened at least annually (high risk includes: <i>injection-drug users and their sex partners, persons who exchange sex for money or drugs, sex partners of HIV-infected persons, men having sex with men or heterosexual persons who themselves or whose sex partners have had more than one sex partner since their most recent HIV test</i>). No written consent required however documentation in the medical record of informed consent is necessary. The patient should be offered an opportunity to ask questions and to decline testing (opt-out).
Osteoporosis Screening ^{21,40}	Women age 65 and older and men age 70 and older, regardless of clinical risk factors (NQF.2010) should be screened routinely for osteoporosis. Routine screening begin at age 60 for women at increased risk for osteoporotic fractures (USPSTF). Bone mineral density testing may be recommended for women who are postmenopausal and younger than 65 years who have at least one risk factor for osteoporosis. Finally, bone mineral density testing should be performed on all women who are postmenopausal with fractures to confirm the diagnosis of osteoporosis and determine the severity of disease (ACOG).
Prostate Cancer Screening ^{29,30,39}	<p>Offer and discuss risks and benefits of a PSA-based screening and digital rectal examinations to detect prostate cancer in men age 50 who are at average risk of prostate cancer and are expected to live at least 10 more years. Discussion should begin at age 45 for men at high risk (African-American men and men with a strong family of one or more first-degree relatives [father, brothers] diagnosed before age 65. Men at even higher risk, due to multiple first-degree relatives affected at an early age, should be counseled at age 40 (ACS). The USPSTF recommends against screening for prostate cancer in men age 75 years or older. Men who choose to be tested who have a PSA of less than 2.5 ng/ml, may only need to be retested every 2 years. Screening should be done yearly for men whose PSA level is 2.5 ng/ml or higher.</p> <p>The American Urological Association recommends that PSA screening, in conjunction with a digital rectal examination, should be offered to asymptomatic men aged 40 years or older who wish to be screened, if estimated life expectancy is greater than 10 years (60). It is currently updating this guideline (61).</p> <p>Note - The American Cancer Society emphasizes informed decision making for prostate cancer screening: men at average risk should receive information beginning at age 50 years, and black men or men with a family history of prostate cancer should receive information at age 45 years (62).</p> <p>The American College of Preventive Medicine recommends that clinicians discuss the potential benefits and harms of PSA screening with men aged 50 years or older, consider their patients' preferences, and individualize screening decisions (63).</p> <p>The American Academy of Family Physicians is in the process of updating its guideline, and the American College of Physicians is currently developing a guidance statement on this topic.</p>

Preventive Service	Guideline
IMMUNIZATIONS ¹¹	For Complete CDC recommendations for Adult Immunizations go to: http://www.cdc.gov/vaccines/recs/schedules/default.htm

Footnotes:

1. ACOG News Release, July 31, 2003, ACOG Office of Communications
2. ACP Task Force on Adult Immunization & Infectious Diseases Society of America, [Guide for Adult Immunization](#), 3rd edition. Rev. 2/99
3. ACP Task Force on Adult Immunization & Infectious Diseases Society of America, [Guide for Adult Immunization](#), 3rd edition. Rev. 2/99
4. AHRQ, (2013). Autism and developmental delays. Retrieved from <http://effectivehealthcare.ahrq.gov/ehc/products/106/708/autism-clinicianfinal.pdf>
5. AHRQ, (2013). Childhood obesity prevention programs: Comparative effectiveness. Retrieved from <http://www.effectivehealthcare.ahrq.gov/ehc/products/330/1713/child-obesity-clinician-130917.pdf>
6. AHRQ, (2013). Screening for hepatitis C virus in adults. Retrieved from http://www.effectivehealthcare.ahrq.gov/ehc/products/285/1283/CER69_HepatitisCScreening_FinalReport_20121015.pdf
7. AHRQ, (2012). Methods for insulin delivery and glucose monitoring: Comparative effectiveness. Retrieved from http://www.effectivehealthcare.ahrq.gov/ehc/products/242/749/CER57_Insulin-Delivery_FinalReport_20120703.pdf
8. AHRQ, (2013). Screening for Hepatitis C virus infection in adults. Retrieved from <http://effectivehealthcare.ahrq.gov/ehc/products/285/1698/hepatitis-c-screening-clinician-130913.pdf>
9. AHRQ, (2013). Pediatric Obesity: Keeping children at a healthy weight. Retrieved from <http://effectivehealthcare.ahrq.gov/ehc/products/330/1714/child-obesity-130916.pdf>
10. AHRQ, (2013). Otitis Media with Effusion: comparative effectiveness of treatments. Retrieved from <http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1485>
- 11.
12. American Academy of Ophthalmology, [Eye Health Screening Guidelines Teens to Adults](#), November 25, 1997. (AAO)
13. American Cancer Society, [Guidelines for the Cancer Related Checkup](#), July 1, 1998 (ACS)
14. American College of Physicians, [Cholesterol Screening Guidelines](#), March 1, 1997 (ACP)
15. American Medical Association Physician Consortium for Performance Improvement: Preventive Care and Screening. Retrieved Nov. 6, 2003 from <http://www.AMA.org>
16. CDC - [Epidemiology and Prevention of Vaccine Preventable Diseases](#), January 1, 1996
17. CDC [Fact Sheets](#), October 10, 1997.
18. Eyre, H., Kahn, R., Robertson, RM. [Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association](#). CA A Cancer Journal for Clinicians, July/August 2004, Volume 54, Number 4.
19. Marshall, JR, Fay, D, Lance, P. [Potential Costs of Flexible Sigmoidoscopy-Based Colorectal Cancer Screening](#). Journal of the American Gastroenterological Association, 1996. (JAGA)
20. Maryland Department of Health and Mental Hygiene, Adult and Childhood Immunization Schedule (<http://www.cdc.gov/vaccines/recs/schedules/default.htm>)
21. National Cholesterol Education Program Expert Panel. Third report of the expert panel on detection, evaluation, and the treatment of high blood cholesterol in adults (Adult Treatment Panel III). Washington, DC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute; 2001.
22. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) *Diabetes Care*, 26:S5-S20, retrieved January 7, 2004 from <http://care.diabetesjournals.org>.
23. Summary of Policy Recommendations for Periodic Health Examinations, American Academy of Family Physicians, April 2005, Revision 5.7.
24. Task Force Recommends Regular Cervical Cancer Screening but Supports Less Frequent Screening for Some Women. Press Release, January 22, 2003. Agency for Healthcare Research and Quality, Rockville, MD. <http://www.ahrq.gov/news/press/pr2003/cervcanpr.htm>
25. USPS Task Force, [Guide to Clinical Preventive Services](#), 2nd ed.; Williams & Wilkins, 1996 (USPS)
26. U.S. Preventive Services Task Force (USPSTF, 2001).
27. U.S. Preventive Services Task Force (USPSTF, 2002) retrieved Jan. 2004 from : <http://www.ahcpr.gov/clinic/uspstfix.htm>.
28. U.S. Preventive Services Task Force (USPSTF, 2005). Screening for Abdominal Aortic Aneurysm: Recommendation Statement.
29. United States Preventive Services Task Force. Screening for depression: recommendations and rationale. *Ann Intern Med* 2002;136:760-4.
30. U.S. Preventive Services Task Force (USPSTF, 2002) Retrieved July, 2005 from: <http://www.ahrq.gov/clinic/3rduspstf/osteoporosis/>
31. The U.S. Preventive Services Task Force (USPSTF) for Primary Prevention of Cardiovascular Events—Chemoprevention Release Date: January 2002
32. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Full Report, September 2002
33. Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings, September 22, 2006 / 55(RR14);1-17 <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm>
34. Clinical Practice Recommendations, American Diabetes Association, Standards of Medical Care in Diabetes—2007 *Diabetes Care* 30: S4-41S.
35. American Cancer Society Guidelines for Breast Cancer Screening: Update 2003 *CA Cancer J Clin* 2003; 53:141-169.
36. Institute for Clinical Systems Improvement, Preventive Services for Adults: Thirteenth Edition/October 2007 Retrieved Nov. 2007 from www.icsi.org.
37. Ophthalmologists Recommend a Check to Establish a Baseline of Eye Health, 2007 American Academy of Ophthalmology retrieved December 2007 from : <http://www.geteyesmart.com/know/screening.cfm>

38. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and Harms of Prostate-Specific Cancer Screening: An Evidence Update for the U.S. Preventive Services Task Force. Evidence Synthesis No. 63. AHRQ Publication No. 08-05121-EF-1. Rockville, Maryland: Agency for Healthcare Research and Quality. August 2008.
39. American Cancer Society, American Cancer Society Guidelines for the Early Detection of Cancer Revised: 03/05/2008
40. The U.S. Preventive Services Task Force (USPSTF), Updated Screening recommendations for Colorectal Cancer, October, 2008. Retrieved: October 2008 from <http://www.ahrq.gov/clinic/uspstf/uspscolo.htm>.
41. U.S. Preventive Services Task Force (USPSTF). Screening for Breast Cancer Recommendation Statement. November 2009, Updated: December 2009 <http://www.ahrq.gov>
42. U.S. Preventive Services Task Force (USPSTF) Screening for Depression in Adults. Recommendation Statement Date: December 2009. <http://www.ahrq.gov>
43. Prevention the Focus of New Colon Cancer Screening Guidelines Retrieved ACS. 2009 from http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Prevention_the_Focus_of_New_Colon_Cancer_Screening_Guidelines.asp
44. New ACOG Cervical Cancer Screening Recommendations .ACOG- 2009. Retrieved December 2009 from: http://www.acog.org/from_home/publications/press_releases/nr11-20-09.cfm
45. The Breast Cancer Risk Assessment Tool is based on a statistical model known as the "Gail model," Retrieved January 2010 from: <http://www.cancer.gov/bcrisktool/>
46. U.S. Preventive Services Task Force (USPSTF) Aspirin for the Prevention of Cardiovascular Disease Recommendation Statement Date: March 2009. <http://www.ahrq.gov> .
47. U.S. Preventive Services Task Force,(2012). Screening for prostate cancer: U.S. Preventive Services Task Force Recommendation Statement. Retrieved from <http://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatefinalrs2.htm>
48. Standards of Medical Care in Diabetes—2010, DIABETES CARE, VOLUME 33, SUPPLEMENT 1, JANUARY 2010. <http://care.diabetesjournals.org> .
49. Recommendations for Prostate cancer early detection, American Cancer Society retrieved March 2010. (http://www.cancer.org/docroot/CRI/content/CRI_2_6x_Prostate_Cancer_Early_Detection.asp)
50. Clinician Guide To The Prevention And Treatment Of Osteoporosis.(http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf) and. Statement by the National Osteoporosis Foundation on Bone Mineral Density Testing. http://nationalosteoporosisfoundation.com/news/pressreleases/20100706-Bone_Mineral_Density_Testing.htm. Retrieved by December 2010.

Pediatric Populations

Preventive Service	GUIDELINE	
	1-18 MONTHS	18 MONTHS - 21 YEARS
Well Child Care Visit Schedule	Prenatal ¹ , 2-4 days ² , 2 wks ² , 1 mo, 2 mo, 4 mo, 6 mo, 9 mo, 12 mo, 15 mo, 18 mo	2 yr, 30 month at discretion of provider, and annually from age 3 years to 21 years
Physical Exam	Every visit	Every visit
<ul style="list-style-type: none"> Height/Weight with percentile 	Every visit	Every visit.
<ul style="list-style-type: none"> Head Circumference with percentile 	Every visit until 24 months	Continue when abnormal results are obtained
<ul style="list-style-type: none"> BMI with percentile^{15, 16, 19} 		24 months, 30 months and then annually ¹⁹
<ul style="list-style-type: none"> Blood Pressure Screening 		Every visit beginning at 3 yr.
<ul style="list-style-type: none"> Growth, development, behavior assessment¹² 	<p>Every visit Growth Parameters reviewed at every well visit</p> <p>Developmental screening should be administered regularly at the 9-, 18-, and 30-month well visits. <i>(Because the 30-month visit is not yet a part of the preventive care system and is often not reimbursable by third-party payers at this time, developmental screening can be performed at 24 months of age. In addition, because the frequency of regular pediatric visits decreases after 24 months of age, a pediatrician who expects that his or her patients will have difficulty attending a 30-month visit should conduct screening during the 24-month visit.) (AAP. 2006)</i></p>	
<ul style="list-style-type: none"> Genital Exam 		External genital exam: Annually.
<ul style="list-style-type: none"> Cervical Cancer Screening¹⁷ 		Cervical cancer screening should begin at age 21 years (regardless of sexual history). <i>Screening before age 21 should be avoided because women less than 21 years old are at very low risk of cancer. Screening these women may lead to unnecessary and harmful evaluation and treatment (ACOG 2009).</i> For immunosuppressed patients screening may start earlier.
<ul style="list-style-type: none"> Nutritional Status 	Assess nutritional status; recommend appropriate counseling or programs for high-risk conditions (overweight: BMI between 85-94% for age and sex, Obesity: BMI \geq 95% for age and sex, or failure to thrive.	
<ul style="list-style-type: none"> Vision & Hearing 	<p>Subjective screening at visits: newborn - 24 mo, 11 yr, 13 yr, 14 yr, 16 yr, 17 yr, 19 yr, 20 yr & 21 yr.</p> <p>Objective Screening at visits: Newborn, 4 yr, 5 yr, 6 yr, 8, 10, 12 yr, 15 yr, 18 yr.</p>	
Dental Health ¹⁴	Oral Health assessment should begin at birth and dental assessment begins at tooth eruption. Recommend dental provider assessment beginning at age 1 or earlier if dental concerns are present. Dentist evaluation should occur every 6 months. (AADP)	

Preventive Service	GUIDELINE	
	1-18 MONTHS	18 MONTHS - 21 YEARS
Counseling / Education / Screening for high-risk factors	One or more of age appropriate counseling should be discussed during periodic primary care physician visits. Additional screening and intervention may be necessary for individuals at high-risk. Anticipatory guidance, substance abuse, smoking, diet and exercise, injury prevention, domestic violence, dental health, sexual behavior, use of alternative and complementary medicines, depression, suicidal/homicidal ideation, high-risk of exposure to infectious diseases (HIV, Hep A, Hep B, Hep C). Parents and caregivers should be advised to place healthy infants on their backs when putting them to sleep. Side positioning is a reasonable alternative but carries a slightly higher risk of SIDS ⁷ .	
Autism ^{13, 20}	Administer autism specific screening tool on all children at the 18 month preventive care visit (2007)	Administer autism specific screening tool on all children at the 2 year preventive care visit. If patient has not been screened in the past, consider screening. (MCHAT is an example of a validated tool).
Sexually Transmitted Diseases (STD) Screening	Infants born to mothers whose HIV status is unknown should be tested for HIV.	Screening for all sexually active adolescents and other asymptomatic persons at high-risk for STDs (includes gonorrhea, Chlamydia, syphilis and HIV).
Blood Lead Testing ^{4, 9, 10}	Blood lead test at between 9-12 months as required by state law	Repeat Blood testing on or after 2 yrs (24 months) as required by state law ° Screening is recommended for previously untested children aged <6 years to rule out subclinically elevated blood lead level. Any positive screen should have a follow up blood test.
Hereditary/Metabolic Screening	Newborn Metabolic screen (PKU) by age one month: should be performed according to state law	Sickle cell screen if not already completed, if status unknown or risk factors.
Tuberculosis Screening ⁵	By age 12 months (Initial testing can begin as early as 3 months).	Assess annually for high-risk. Perform TB screening with tuberculin skin test if high-risk factors are present (i.e. medically underserved, immunocompromised, close contact with TB cases, medical risk factors, immigrants from high prevalence areas)
Hematocrit or Hemoglobin Screening ³	Consider screening once in all infants between 9-12 months. Must screen high risk groups at 9-12mos and again 6-12 months later.**	Females should be screened at least once after regular menstruation.
Cholesterol Screening ^{6, 18}		2 to 21 years: Perform cholesterol screening for high-risk patients with blood fasting lipid profile. Risk factors for premature cardiovascular disease include obesity, high blood pressure, diabetes, family history of dyslipidemia and family history of premature cardiovascular disease (males <55yrs and female <65yrs). If hypercholesterolemia is identified then recommendations are to include nutritional guidance and/or referral to weight management program or nutritionist. Lipid lowering agents may be considered in children 8 yrs or older who have failed diet management and continue with hypercholesterolemia.
Diabetes Screening		Beginning at age 10 years or at onset of puberty, fasting glucose recommended for overweight individual (BMI> 85 th percentile) every 2 years and should also be based on other risk factors such as lifestyle and/or family history and HbA1c should be performed.

Preventive Service	GUIDELINE	
	1-18 MONTHS	18 MONTHS - 21 YEARS
Depression screening ¹¹		Screening of adolescents (12 and older-18 years of age) for major depressive disorder (MDD), suicidal/homicidal ideation, and recommend follow-up as appropriate to a mental health provider. Validated screening tools include: PHQ-9A, GAPS, and Teen Screen.
Urinalysis Screening		Routine urinalysis to screen for kidney disease is not required.
• Contraception Management		Screening pelvic exams are not recommended. Age appropriate contraceptive management should be offered as part of preventive health maintenance.
IMMUNIZATIONS⁸	For Complete CDC recommendations for Pediatric Immunizations go to; http://www.cdc.gov/vaccines/recs/schedules/default.htm	

**** High risk populations include children who are: in poverty, Black, Native American, Alaska native, immigrant, preterm and low birth weight infants, infants drinking cow's milk**

Footnotes:

¹A prenatal visit is recommended for parents who are at high-risk, for first time parents, and or those who request a conference. The prenatal visit should include anticipatory guidance, pertinent medical history and a discussion of benefits of breastfeeding and planned method of feeding per AAP statement "The Prenatal Visit" (1996).

²Every infant should have a newborn evaluation after birth. Breastfeeding should be encouraged and instruction and support offered. Every breastfeeding infant should have an evaluation 48-72 hours after discharge from the hospital and again at 2 weeks of age if appropriate. Visit to include weight, bilirubin assessment, formal breastfeeding evaluations, encouragement, and instruction as recommended in the AAP statement "Breastfeeding and the Use of Human Milk" (1997).

³Recommendations to Prevent and Control Iron Deficiency in the United States. MMWR 1998;47 (RR-3):1-29

⁴American Academy of Pediatrics. (June 1998). Screening for Elevated Blood Lead Levels (RE9815).

⁵TB testing per recommendations of the Committee on Infectious Diseases, published in the current edition of RED BOOK: Report of the Committee on Infectious Diseases. Testing should be done upon recognition of high-risk factors.

⁶American Academy of Pediatrics. (January 1998). Cholesterol in Childhood (RE9805).

⁷AAP Statement "Changing Concepts of Sudden Infant Death Syndrome: Implications for Infant Sleeping Environment and Sleep Position" (2000).

Adapted from multiple sources including:

- a. American Academy of Pediatrics. Recommendations for Preventive Pediatric Health Care (RE9535)(2000)
- b. The Maryland Healthy Kids Program. Schedule of Preventive Health Care (9/99). American Cancer Society.
- c. Centers for Disease Control and Prevention.
- d. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd Edition. Washington, DC: U.S. Department of Health and Human Services, 1996.
- e. Consensus by the Committee of Practice and Ambulatory Medicine in Consultation with National Committee and the American Academy of pediatrics March 2000. Academy of General Dentistry May 2002.
- f. American Academy of Pediatrics. In: Pickering L.K., ed. Red Book, 2003 Report of Infectious Diseases. 26th ed.

⁸. Maryland Department of Health and Mental Hygiene, Adult and Childhood Immunization Schedule (<http://www.cdc.gov/vaccines/recs/schedules/default.htm>)

⁹ PEDIATRICS (October 2005), Vol. 116 No. 4 pp. 1036-1046 (doi:10.1542/peds.2005-1947). Lead Exposure in Children: Prevention, Detection, and Management

¹⁰ Recommendations for Blood Lead Screening of Young Children Enrolled in Medicaid: Targeting a Group at High Risk, MMR December 08, 2000 / 49(RR14);1-13

¹¹ U.S. Preventive Services Task Force (USPSTF). Screening and Treatment for Major Depressive Disorder in Children and Adolescents. Recommendation Statement. Date: March 2009

¹² Identifying Infants and Young Children with Developmental Disorders in the Medical Home: An Algorithm for Developmental Surveillance and Screening. July 2006, Policy statement AAP. (<http://aappolicy.aappublications.org/cgi/reprint/pediatrics;118/1/405.pdf>)

¹³ Identification and Evaluation of Children with Autism Spectrum Disorders. Pediatrics, Volume 120, November 2007. (www.pediatrics.org/cgi/doi/10.1542/peds.2007-2361)

¹⁴ Guideline on Infant Oral Health, Clinical Guidelines, American Academy of Pediatric Dentistry, V 31, No.6, 2009 (<http://www.aapd.org>)

¹⁵ U.S. Preventive Services Task Force (USPSTF), January 2010. Screening for Obesity in Children and Adolescents (<http://www.ahrq.gov/clinic/uspstf10/childobes/chobesrs.htm#copyright>)

- ¹⁶ Barlow SE, Dietz WH. Obesity evaluation and treatment: Expert Committee recommendations. *Pediatrics* 1998;102(3). Available at: <http://www.pediatrics.org/cgi/content/full/102/3/e29>
- ¹⁷ New ACOG Cervical Cancer Screening Recommendations .ACOG- 2009. Retrieved December 2009 from: http://www.acog.org/from_home/publications/press_releases/nr11-20-09.cfm
- ¹⁸ Lipid Screening and Cardiovascular Health in Childhood. PEDIATRICS Vol. 122 No. 1 July 2008, pp. 198-208 (doi:10.1542/peds.2008-1349) Retrieved from: <http://aappolicy.aappublications.org/cgi/content/full/pediatrics;122/1/198>.
- ¹⁹ AAP: Recommendations for Preventive Pediatric Health Care. <http://brightfutures.aap.org/pdfs/AAP%20Bright%20Futures%20Periodicity%20Sched%20101107.pdf> Retrieved 2.21.2010.
- ²⁰ The [Modified Checklist for Autism in Toddlers](http://www2.gsu.edu/~psydlr/Diana_L_Robins_Ph.D.html) (M-CHAT™; Robins, Fein, & Barton, 1999, http://www2.gsu.edu/~psydlr/Diana_L_Robins_Ph.D.html)

Recommendations for Patient Education Resources

Immunizations:

1. Immunization Action Coalition, The Coalition is a non-profit organization that promotes appropriate immunization against vaccine-preventable diseases. The website offers a wealth of information including many educational pieces for parents/patients. <http://www.immunize.org>, admin@immunize.org
2. Vaccine Information for the Public and Health Professionals, <http://www.vaccineinformation.org>, admin@vaccineinformation.org
3. National Vaccine Program Office (NVPO) www.hhs.gov/nvpo
NVPO is federal program which provides pertinent information about childhood, adolescent, and adult immunizations. Their site offers publications and reports on vaccine-preventable diseases, vaccine safety, vaccine coverage, immunization laws, and immunization registries
4. CDC's Immunization Information Hotline: (800) 232-2522 (English) (800) 232-0233 (Spanish)

Screening Recommendations:

1. American Academy of Family Physicians. (<http://www.aafp.org/>)
 - a. [Breast Cancer Screening Counseling Tools](http://www.aafp.org/x19497.xml) -- Access tools that may be used to facilitate shared decision-making regarding screening for breast cancer in women aged 40-49 years. (<http://www.aafp.org/x19497.xml>)
 - b. [Prostate Cancer Screening Counseling Tools](http://www.aafp.org/x19497.xml) -- Find tools that are intended to be used to facilitate shared decision-making regarding screening for prostate cancer in men aged 50-65 years. (<http://www.aafp.org/x19497.xml>)
2. AHRQ, (2013). Autism and developmental delays. Retrieved from <http://effectivehealthcare.ahrq.gov/ehc/products/106/708/autism-clinicianfinal.pdf>
3. AHRQ, (2013). Childhood obesity prevention programs: Comparative effectiveness. Retrieved from <http://www.effectivehealthcare.ahrq.gov/ehc/products/330/1713/child-obesity-clinician-130917.pdf>
4. AHRQ, (2012). Methods for insulin delivery and glucose monitoring: Comparative effectiveness. Retrieved from http://www.effectivehealthcare.ahrq.gov/ehc/products/242/749/CER57_Insulin-Delivery_FinalReport_20120703.pdf
5. AHRQ, (2013). Screening for Hepatitis C virus infection in adults. Retrieved from <http://effectivehealthcare.ahrq.gov/ehc/products/285/1698/hepatitis-c-screening-clinician-130913.pdf>
6. AHRQ, (2013). Pediatric Obesity: Keeping children at a healthy weight. Retrieved from <http://effectivehealthcare.ahrq.gov/ehc/products/330/1714/child-obesity-130916.pdf>
7. AHRQ, (2013). Otitis Media with Effusion: comparative effectiveness of treatments. Retrieved from <http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1485>
8. U.S. Preventive Services Task Force (USPSTF) Web site page that provides tools and resources to support public and private health care based on USPSTF recommendations (<http://www.ahrq.gov/clinic/ppipix.htm>).

9. Task Force on Community Preventive Services: (<http://www.thecommunityguide.org/>)
All material on this site is public domain and we encourage copying and disseminating freely. However, citation to source is appreciated.
10. U.S. Preventive Services Task Force (USPSTF). Screening for Breast Cancer Recommendation Statement. November 2009, Updated: December 2009 <http://www.ahrq.gov>
11. U.S. Preventive Services Task Force (USPSTF) Screening for Depression in Adults. Recommendation Statement Date: December 2009. <http://www.ahrq.gov>
12. Prevention the Focus of New Colon Cancer Screening Guidelines Retrieved ACS. 2009 from http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Prevention_the_Focus_of_New_Colon_Cancer_Screening_Guidelines.asp
13. New ACOG Cervical Cancer Screening Recommendations .ACOG- 2009. Retrieved December 2009 from: http://www.acog.org/from_home/publications/press_releases/nr11-20-09.cfm
14. The Breast Cancer Risk Assessment Tool is based on a statistical model known as the "Gail model," Retrieved January 2010 from: <http://www.cancer.gov/bcrisktool/>
15. U.S. Preventive Services Task Force (USPSTF) Aspirin for the Prevention of Cardiovascular Disease Recommendation Statement Date: March 2009. <http://www.ahrq.gov> .
16. Standards of Medical Care in Diabetes—2010, DIABETES CARE, VOLUME 33, SUPPLEMENT 1, JANUARY 2010. <http://care.diabetesjournals.org>